Balyasny Asset Management LLC Bristol Myers Squibb CO Transaction History

Balyasny Asset Management LLC

$61.9 Billion
Q2 2025

A detailed history of Balyasny Asset Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Balyasny Asset Management LLC holds 26,500 shares of BMY stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,500

Previous 64,900 59.17%

Holding current value

$1.22 Million

Previous $3.96 Million 69.02%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$44.12 - $59.6 $1.99 Million - $2.69 Million	45,139 New	45,139 $2.09 Million
Q4 2024 Feb 14, 2025	SELL	$51.92 - $59.94 $26.8 Million - $30.9 Million	-515,384 Reduced 59.75%	347,220 $19.6 Million
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $33.9 Million - $44.2 Million	854,600 Added 10677.16%	862,604 $44.6 Million
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $1.86 Million - $2.45 Million	-46,320 Reduced 85.27%	8,004 $332,000
Q1 2024 May 13, 2024	SELL	$47.98 - $54.4 $1.08 Million - $1.23 Million	-22,594 Reduced 29.37%	54,324 $2.95 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $46.6 Million - $55.6 Million	-960,724 Reduced 92.59%	76,918 $3.95 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $8.51 Million - $9.52 Million	147,039 Added 16.51%	1,037,642 $60.2 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $18.4 Million - $20.4 Million	288,296 Added 47.87%	890,603 $57 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $39.6 Million - $44.9 Million	602,307 New	602,307 $41.7 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $31,115 - $18.4 Million	239,352 Added 49.95%	718,488 $51.1 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $2.12 Million - $2.33 Million	29,171 Added 6.48%	479,136 $36.9 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $4.95 Million - $5.93 Million	-80,473 Reduced 15.17%	449,965 $32.9 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $24.6 Million - $28.8 Million	415,856 Added 362.93%	530,438 $31.4 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $33 Million - $35.9 Million	-532,898 Reduced 82.3%	114,582 $7.66 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $14.1 Million - $15.9 Million	238,438 Added 58.29%	647,480 $40.9 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $22.9 Million - $26 Million	396,948 Added 3282.19%	409,042 $25.4 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $17.3 Million - $20.2 Million	-315,551 Reduced 96.31%	12,094 $711,000
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $10.8 Million - $15.6 Million	232,090 Added 242.89%	327,645 $18.3 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $1.42 Million - $1.85 Million	28,794 Added 43.13%	95,555 $6.13 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $12 Million - $13.3 Million	-269,704 Reduced 80.16%	66,761 $3.03 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $2.94 Million - $3.51 Million	65,168 Added 24.02%	336,465 $16.1 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $39.2 Million - $50.9 Million	-804,944 Reduced 74.79%	271,297 $14.1 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $28.8 Million - $32.5 Million	521,635 Added 94.06%	1,076,241 $66.8 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $6.18 Million - $7.7 Million	122,271 Added 28.28%	554,606 $30.7 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $40.7 Million - $46.9 Million	-679,353 Reduced 61.11%	432,335 $27.3 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $26.4 Million - $28.8 Million	-441,171 Reduced 28.41%	1,111,688 $68.1 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $85.8 Million - $99 Million	1,552,859	1,552,859 $99 Million

Others Institutions Holding BMY

# of Institutions

2,668

Shares Held

1.64B

Call Options Held

22.5M

Put Options Held

25.3M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $98B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Bristol Myers Squibb CO Transaction History